Clearpoint Neuro Inc. · NASDAQ:CLPT
Clearpoint Neuro — Investor Presentation (November 2021)
28 slides from Clearpoint Neuro's investor presentation, Nov 9, 2021
Slide 1: ClearPoint Neuro: When your path is clear, we point the way
CLEARPOINT NEURO WHEN YOUR PATH IS WE POINT THE WAY. Nasdaq: CLPT November 2021
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS Statements herein concerning the Company’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's
Slide 3: ClearPoint Neuro: Two Opportunities, One Platform
Our Company ClearPoint Neuro: Two Opportunities, One Platform A Biologics & Drug Delivery Company with a Broad Portfolio of Pharma Partners and Indications with Potentially Explosive Growth * 2020 Growth of 109% during COVID ise CLEARPOINT CLEARPOINT NEURC $1B+ Potential Market, first indication exp
Slide 4: ClearPoint Neuro: A Proven Platform
Our Company ClearPoint Neuro: A Proven Platform Key Products: FDA. C€ Marked Platforms HEADQUARTERS. Solana Beach, CA 2020 REVENUE °12.8m U.S. PATENTS ISSUED 65 EMPLOYEES 70+ 30+ field 40+ production & development (A) As of, and for the quarter ended, September 30, 2021 CLEARPOINT MANUFACTURING EURO
Slide 5: Limitations of Traditional Stereotactic Neurosurgery
Limitations of Traditional Stereotactic Neurosurgery Lack of Real-Time Image Guidance PRIMARY CHALLENGE For minimally invasive procedures to be successful, the surgeon needs imaging to see into the head MRI is the best imaging tool for the brain Large, metallic frames are not MRI compatible CLEARPOI
Slide 6: Our Platform — Procedure Overview
Our Platform — Procedure Overview The ClearPoint® Neuro Navigation System 388; CLEARPOINT © 2024 CLEARPOINT NEURO 6 38° NEURO
Slide 7: SmartFrame XG and SmartFrame Array
SmartFrame® XG SmartFrame Array™ jroped SmartFrame Array Tower* with “virtual array” Software and next generation robotic system with increased automation and enabling software SmartFrame XG Trajectory Tower with ClearPoint 2.0 Software es CLEARPOINT © 2021 CLEARPOINT NEURO 7 *The SmartFrame Array T
Slide 8: The ClearPoint Maestro Brain Model
Our Platform The ClearPoint ‘Maestro’ Brain Model” Licensed and Jointly Developed with Philips 1. Shape Constrained, triangular mesh model enables point-based correspondence across multiple subjects 2. Fast and capable of peri-procedural imaging without CPU acceleration 3. This model is the basis fo
Slide 9: Our MRI-guided therapy platform
Our MRI-guided therapy platform is currently being used to... SIEMENS IMRIS es CLEARPOINT PTC) Medtronic Ske =) Abbott ys seit GENE uniQure NELRO charles river .. with ~40 total commercial and academic partners Medtronic MONTERIS MEDICAL © 2021 CLEARPOINT NEURO
Slide 10: Broad Clinical Use Base
Broad af enuiie Use Bas : 60+ Genrer. in vthe U an esing Joba) : x Charles Riv er Labs (Lavdil,. Canada) ( % Rigshospitalet en hi Denmark) - Stanford University’ =U ichigan- . Children’s Mercy Hospital . i Szpital Brodnowski (Warsaw, Poland) ) Stanford Children’s Hospital Unive Min ot _ _CHOAScottis
Slide 11: Biologics & Drug Delivery
Biologics & Drug Delivery © 2021 CLEARPOINT NEURO
Slide 12: Why ClearPoint?
Why ClearPoint? Benefits of ClearPoint 1. Select and confirm the most accurate trajectory before insertion using live MRI Guidance 2. Identify peri-procedural safety issues live instead of after the patient is closed (i.e., hemorrhage) 3. Confirm proper target coverage with drug before closing the p
Slide 13: Patient Treatment Opportunity per Year
PATIENT TREATMENT OPPORTUNITY/YEAR 1. Biologics & Drug Delivery Estimated $1.5B* Market Opportunity As Platform for G 200,000 Parkinson’s Disease** 100,000 ~$1.2B3 Epilepsy** 10,000 =S360M4 Huntington Disease** ~$120M? Angelman _ 5,000 Syndrome** r Friedreich’s ~$72M" Multiple System Ataxia** Atroph
Slide 14: Specialized Consultation for Pharmaceutical Customers
1. Biologics & Drug Delivery Specialized Consultation for Pharmaceutical Customers Custom Protocol Solutions for Cannula Builds Consultation Pre-Clinical Programs 3 fs Network of Data Neurosurgeons Management ise CLEARPOINT © 2021 CLEARPOINT NEURO 14
Slide 15: Navigation Device & Therapy
Navigation Device & Therapy © 2021 CLEARPOINT NEURO
Slide 16: Deep Brain Stimulation
Deep Brain ‘Stimulation The ClearPoint® Neuro Navigation Platform is used to accurately place leads in the appropriate targeted structure. The leads are connected in a separate procedure to a neurostimulator implanted near the collarbone. Deep brain stimulation (DBS) uses a surgically implanted medi
Slide 17: Neuro Navigation (DBS): Gaining Share in a Growing Market
2. Neuro Navigation (DBS} Deep Brain Stimulation Gaining Share in a Growing Market Boccia Medtronic GS) Abbott NEUROPACE Parkinson’s Patient Population (US) 2019 Patient: ith 400 1.2M tients wi . Parkinson’s disease 12,000 %; 6,000 are implants ° % , ; Implants/yr & lead implants ~ 1M Patients diagn
Slide 18: Improved Navigation & Technology, New Indications Drive DBS Growth
2. Neuro Navigation (DBS) Improved Navigation & Technology, New Indications Drive DBS Market Growth of 10%+ CAGR 2020-2025 New Indications in Trials | Treatment Populations Neurosurgical Targets Pilot Phase I/II Phase Ill © Commercial Epilepsy" 2 millions Multiple Po Obsessive Compulsive ant Ventral
Slide 19: New Therapy Devices: Laser Therapy
3. New Therapy Devices ClearPoint Neuro Laser Therapy — Capturing the Entire Procedure LITT uses laser energy to destroy unwanted cells * Today MRI is required during LITT procedures to precisely monitor and control the temperature and thermal dose from that laser. * ClearPoint is chosen by Neurosur
Slide 20: Significant Addressable Neuro Market in Epilepsy and Tumor
3. New Therapy Devices ClearPoint Neuro Laser Therapy™ — Capturing the Entire Procedure Significant Addressable Neuro Market in Epilepsy and Tumor Medtronic —-°-.°. MONTER!S LiTT for Epilepsy - Total Addressable Patient Population (US) Navigation 150K Patients with Epilepsy ($6,000) 2020 50K Epilept
Slide 21: New Global Showcase Site
New Global Showcase Site ClearPoint Global Training & Innovation Center — Solana Beach, CA Intimate training experience for surgeons and staff to perform mock procedures and provide pipeline feedback Showcase new technology for Pharmaceutical Drug Delivery partners Home for remote support specialist
Slide 22: Innovation: Accelerated Product Pipeline
Innovation Accelerated Product Pipeline and Target First Clinical Use Navigation & Robotics & 2020-21 Inflexion™ Head Fixation Frame. SmartFrame Array™! 2022 ClearPoint Neuro Navigation Software v. 2.1? rs ClearPoint Maestro™ Brain Model” 2023 ve aS ee ClearPoint Maestro™ Sub Nuclei App? Robotic-Ass
Slide 23: Pillar Growth Strategy by 2025
4 Pillar Growth Strategy by 2025 Target Indications of > 300,000 procedures per year represents Potential Addressable Market for CLPT of $2B+ 2020 es CLEARPOINT GLOBAL SCALE Expand Footprint OUS Open WW Training / Remote Support Facility Launch Robotic Platform NEW THERAPY DEVICES Launch Maestro Bra
Slide 24: mlatclatelfslis
mlatclatelfslis
Slide 25: Growth in Case Volume and Revenue
2013 - 2021 Growth in Case Volume and Revenue 629 503 380 267 2013 2014 2015 2016 2017 2018 2019 2020 2021 Estimated FY21 Case Volume 1,000 900 801 “cOvID YZ impact on Elective Procedures 670 682 CLEARPOINT Biologics and Drug Delivery = Capital and Software Functional Neurosurgery $ Millions 2014 20
Slide 26: CLPT Capabilities: Executive Summary
CLPT Capabilities Executive Summary El “SG alll fee CLEARPOINT Unique Platform technology enabling Precision MRI-Guided Therapies to restore quality of life for some of the most debilitating disorders Pipeline of new revenue streams from product improvements, biologic and drug delivery partnerships,
Slide 27: Nasdaq
2 ie Nasdaq Composite Nasdaq100 so at 99 + 0.18% COMP 40.20% 40.29% DJI v0. ae 0.18% +19.21 9,731.18 +2788 9,623.58 c °. amazon” prt ol Bee 0.74% wa ee00 aS Rid COMCAST pepsico matchaioup ER guesa *0,04% Pep *0.36% rcH *1,72% SBUX 10.72% AMZN a © 2021 CLEARPOINT NEURO -\ A Sk =
Slide 28: ClearPoint Neuro
CLEARPOINT NEURO S A, Wy emit = AZ CL pS \\ ZX" Si] NSE RA
ClearPoint Neuro — Investor Presentation (November 2021) on 6ix